AR041854A1 - Derivados de [6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-sulfonilamino]-propionamida utiles como antiinflamatorios - Google Patents

Derivados de [6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-sulfonilamino]-propionamida utiles como antiinflamatorios

Info

Publication number
AR041854A1
AR041854A1 ARP030103945A ARP030103945A AR041854A1 AR 041854 A1 AR041854 A1 AR 041854A1 AR P030103945 A ARP030103945 A AR P030103945A AR P030103945 A ARP030103945 A AR P030103945A AR 041854 A1 AR041854 A1 AR 041854A1
Authority
AR
Argentina
Prior art keywords
imidazol
group
propionamide
derivatives
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP030103945A
Other languages
English (en)
Inventor
Terence Alfred Kelly
Jim Mi Kim
Rene M Lemieux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR041854A1 publication Critical patent/AR041854A1/es
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados de [6,7-dihidro-5H-imidazol[1,2-a]imidazol-3-sul-fonil-amino]-propionamida que muestren buen efecto inhibidor sobre la interacción de CAM (Molécula de Adhesión Celular) y leucointegrinas y son así útiles en el tratamiento de enfermedades inflamatorias. Composiciones farmacéuticas que los contienen y método de preparación de los compuestos. Reivindicación 1: Un compuesto de la fórmula (1), en que: R1 es alquilo lineal o ramificado C1-3 que está opcionalmente mono o disustituido con restos independientes seleccionados del grupo que consiste en: oxo; y morfolino; R2 y R3 se seleccionan cada uno, independientemente, del grupo que comprende: a) hidrógeno, y b) alquilo lineal o ramificado C1-4 cuyo grupo alquilo está mono- o di-sustituido con restos independientemente seleccionados del grupo que consiste en: CONH2; y OH; o R2 y R3 juntos con el átomo de nitrógeno entre ellos forman un anillo de piperazina; y R4 es: a) ciano, b) pirimidina que está mono o disustituida con NH2 o c) trifluorometoxi; o una de sus sales.
ARP030103945A 2002-10-30 2003-10-29 Derivados de [6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-sulfonilamino]-propionamida utiles como antiinflamatorios Suspension/Interruption AR041854A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42244602P 2002-10-30 2002-10-30

Publications (1)

Publication Number Publication Date
AR041854A1 true AR041854A1 (es) 2005-06-01

Family

ID=32312506

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103945A Suspension/Interruption AR041854A1 (es) 2002-10-30 2003-10-29 Derivados de [6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-sulfonilamino]-propionamida utiles como antiinflamatorios

Country Status (32)

Country Link
US (4) US6844360B2 (es)
EP (1) EP1560830B1 (es)
JP (1) JP4366477B2 (es)
KR (1) KR20050067426A (es)
CN (1) CN1708500A (es)
AR (1) AR041854A1 (es)
AT (1) ATE343582T1 (es)
AU (1) AU2003284938A1 (es)
BR (1) BR0315836A (es)
CA (1) CA2504219A1 (es)
CO (1) CO5690604A2 (es)
CY (1) CY1106258T1 (es)
DE (1) DE60309344T2 (es)
DK (1) DK1560830T3 (es)
EA (1) EA008443B1 (es)
EC (1) ECSP055823A (es)
ES (1) ES2276134T3 (es)
HR (1) HRP20050387A2 (es)
MX (1) MXPA05004480A (es)
MY (1) MY136822A (es)
NO (1) NO20052579L (es)
NZ (1) NZ540269A (es)
PE (1) PE20040782A1 (es)
PL (1) PL375709A1 (es)
PT (1) PT1560830E (es)
RS (1) RS20050327A (es)
SI (1) SI1560830T1 (es)
TW (1) TW200424204A (es)
UA (1) UA80160C2 (es)
UY (1) UY28049A1 (es)
WO (1) WO2004041827A2 (es)
ZA (1) ZA200502701B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
EP1712553A3 (en) * 2002-10-30 2006-11-02 Boehringer Ingelheim Pharmaceuticals, Inc. Derivates of [6, 7-dihydro - 5H - imidazo[1,2- alpha]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of CAMS and leukointegrins
US8699508B2 (en) * 2003-12-18 2014-04-15 Intel Corporation Response scheduling for multiple receivers
CA2573398A1 (en) * 2004-07-27 2006-02-09 Boehringer Ingelheim International Gmbh Synthesis of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid amides
US7589114B2 (en) * 2005-04-06 2009-09-15 Boehringer Ingelheim International Gmbh Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-azetidine-carboxylic acids, esters and amides
KR20080025067A (ko) * 2005-05-19 2008-03-19 베링거 인겔하임 인터내셔날 게엠베하 6,7-디하이드로-5Ｈ-이미다조[1,2-ａ]이미다졸-3-설폰산의유도체
US20070173517A1 (en) * 2006-01-20 2007-07-26 Thomas Wirth Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides
NZ585640A (en) * 2007-11-29 2011-03-31 Boehringer Ingelhelheim Internat Gmbh Derivatives of 6,7-dihydro-5h-imidazo[1,2-alpha]imidazole-3- carboxylic acid amides
PL2445909T3 (pl) * 2009-06-02 2014-04-30 Boehringer Ingelheim Int Pochodne amidów kwasu 6,7-dihydro-5H-imidazo[1,2-a]imidazolo-3-karboksylowego
EP2445914B1 (en) * 2009-06-02 2015-07-22 Boehringer Ingelheim International GmbH DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
WO2021217041A1 (en) * 2020-04-24 2021-10-28 Immvention Therapeutix N-substituted alpha-amino and alpha-hydroxy carboxamide derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL336580A1 (en) 1997-03-03 2000-07-03 Boehringer Ingelheim Pharma Fine-molecular compounds useful in treating inflammatory diseases
US6355664B1 (en) 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
MXPA03000914A (es) * 2000-08-09 2003-10-06 Boehringer Ingelheim Pharma Sintesis de (r)-3-(4 -bromobencil) -1-(3, 5-diclorofenil) -5-yodo-3 -metil-1-h -imidazo[1, 2-a]imidazol -2-ona.
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide

Also Published As

Publication number Publication date
WO2004041827A2 (en) 2004-05-21
PL375709A1 (en) 2005-12-12
ATE343582T1 (de) 2006-11-15
NZ540269A (en) 2007-05-31
WO2004041827A3 (en) 2004-07-15
HRP20050387A2 (en) 2006-10-31
SI1560830T1 (sl) 2007-02-28
TW200424204A (en) 2004-11-16
RS20050327A (en) 2007-06-04
JP2006508947A (ja) 2006-03-16
NO20052579L (no) 2005-05-27
US20080090819A1 (en) 2008-04-17
US7589115B2 (en) 2009-09-15
BR0315836A (pt) 2005-09-13
EP1560830B1 (en) 2006-10-25
UY28049A1 (es) 2004-05-31
CY1106258T1 (el) 2011-06-08
PE20040782A1 (es) 2004-12-16
ZA200502701B (en) 2005-10-13
US20050165027A1 (en) 2005-07-28
EP1560830A2 (en) 2005-08-10
ES2276134T3 (es) 2007-06-16
US20050054703A1 (en) 2005-03-10
UA80160C2 (en) 2007-08-27
MY136822A (en) 2008-11-28
CN1708500A (zh) 2005-12-14
CO5690604A2 (es) 2006-10-31
DK1560830T3 (da) 2007-02-26
ECSP055823A (es) 2005-08-11
PT1560830E (pt) 2007-01-31
DE60309344T2 (de) 2007-02-08
DE60309344D1 (de) 2006-12-07
US7345074B2 (en) 2008-03-18
KR20050067426A (ko) 2005-07-01
CA2504219A1 (en) 2004-05-21
EA200500603A1 (ru) 2005-10-27
JP4366477B2 (ja) 2009-11-18
MXPA05004480A (es) 2005-07-26
US6844360B2 (en) 2005-01-18
US20040127534A1 (en) 2004-07-01
US7304067B2 (en) 2007-12-04
EA008443B1 (ru) 2007-06-29
AU2003284938A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
CO5690604A2 (es) Derivados de [6,7-dihidro-5h-imidazo[1.2-alfa]imidazol-3- sulfonilamino]-propionamida
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
AR047917A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
SE0302487D0 (sv) Novel compounds
PA8603801A1 (es) Derivados de la quinazolina
AR057325A1 (es) Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
ATE369370T1 (de) Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
ATE390415T1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
BRPI0514750A (pt) derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
BRPI0408347A (pt) derivados de pirimidina
ATE433981T1 (de) Heterocyclische verbindungen
PA8783601A1 (es) Derivados de piperidina/piperazina
AR056888A1 (es) Derivados de heterociclil imidazol
UY27986A1 (es) Nuevas quinazolinonas espirocondensadas y su uso c omo inhibidores de la fosfodiesterasa
MX2010000658A (es) Derivados de pirimidina 934.
SE0302323D0 (sv) Novel compounds
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
CR10974A (es) Inhibidores de carboxipeptidasa b plasmatica (divisional)
AR055666A1 (es) Inhibidores inntr

Legal Events

Date Code Title Description
FB Suspension of granting procedure